# FDA Approves Zydus Pharmaceuticals' Generic Fluorescein Sodium Injection Zydus Pharmaceuticals USA Inc. received FDA approval for its generic fluorescein sodium intravenous injection, expanding competition in the diagnostic imaging market and potentially lowering costs for ophthalmological and angiography procedures. The approval of the ANDA is expected to provide healthcare providers with an additional cost-effective alternative for fluorescein-based diagnostic applications.